MX2020009183A - Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). - Google Patents
Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).Info
- Publication number
- MX2020009183A MX2020009183A MX2020009183A MX2020009183A MX2020009183A MX 2020009183 A MX2020009183 A MX 2020009183A MX 2020009183 A MX2020009183 A MX 2020009183A MX 2020009183 A MX2020009183 A MX 2020009183A MX 2020009183 A MX2020009183 A MX 2020009183A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- sgc stimulator
- present disclosure
- sgc
- stimulator
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente descripción se relaciona con formas cristalinas de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1H- 1,2,4-triazol-5-il)im idazo[1,2-a]pirazina, que son útiles como estimuladores de guanilato ciclasa soluble (sGC). La presente descripción también provee composiciones farmacéuticamente aceptables que comprenden las formas cristalinas y métodos para usar las composiciones en el tratamiento de diversas afecciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862639846P | 2018-03-07 | 2018-03-07 | |
PCT/US2019/021080 WO2019173551A1 (en) | 2018-03-07 | 2019-03-07 | Crystalline forms of an sgc stimulator |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020009183A true MX2020009183A (es) | 2020-10-08 |
Family
ID=65818696
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023004858A MX2023004858A (es) | 2018-03-07 | 2019-03-07 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
MX2023004857A MX2023004857A (es) | 2018-03-07 | 2019-03-07 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
MX2023004855A MX2023004855A (es) | 2018-03-07 | 2019-03-07 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
MX2023004856A MX2023004856A (es) | 2018-03-07 | 2019-03-07 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
MX2020009183A MX2020009183A (es) | 2018-03-07 | 2019-03-07 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023004858A MX2023004858A (es) | 2018-03-07 | 2019-03-07 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
MX2023004857A MX2023004857A (es) | 2018-03-07 | 2019-03-07 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
MX2023004855A MX2023004855A (es) | 2018-03-07 | 2019-03-07 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
MX2023004856A MX2023004856A (es) | 2018-03-07 | 2019-03-07 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
Country Status (20)
Country | Link |
---|---|
US (2) | US11466015B2 (es) |
EP (1) | EP3762389B1 (es) |
JP (1) | JP7423539B2 (es) |
KR (1) | KR20200128708A (es) |
CN (1) | CN111836812A (es) |
AU (1) | AU2019231724A1 (es) |
BR (1) | BR112020018212A2 (es) |
CA (1) | CA3092683A1 (es) |
CL (5) | CL2020002284A1 (es) |
CO (1) | CO2020012493A2 (es) |
CR (1) | CR20200458A (es) |
EA (1) | EA202092109A1 (es) |
IL (1) | IL276853A (es) |
MA (1) | MA54638A (es) |
MX (5) | MX2023004858A (es) |
PE (1) | PE20210124A1 (es) |
PH (1) | PH12020551394A1 (es) |
SG (1) | SG11202008641WA (es) |
TW (1) | TWI823903B (es) |
WO (1) | WO2019173551A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210177846A1 (en) * | 2018-07-11 | 2021-06-17 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS |
US20230130739A1 (en) * | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途 |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
CA2336807C (en) | 1998-07-08 | 2010-04-13 | Aventis Pharma Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
CA2698332C (en) | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
EP2244575B1 (en) | 2008-01-24 | 2013-07-17 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
EP2373317B1 (en) | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US9365574B2 (en) | 2010-05-27 | 2016-06-14 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
CN104327107A (zh) | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
JP2017537922A (ja) | 2014-12-02 | 2017-12-21 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ピラゾロ[1,5−a]ピリジンおよびイミダゾ[1,2−a]ピラジンならびにそれらの使用 |
CR20190101A (es) | 2016-09-02 | 2019-07-04 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
-
2019
- 2019-03-07 MX MX2023004858A patent/MX2023004858A/es unknown
- 2019-03-07 WO PCT/US2019/021080 patent/WO2019173551A1/en unknown
- 2019-03-07 JP JP2020546378A patent/JP7423539B2/ja active Active
- 2019-03-07 PE PE2020001347A patent/PE20210124A1/es unknown
- 2019-03-07 EA EA202092109A patent/EA202092109A1/ru unknown
- 2019-03-07 MA MA054638A patent/MA54638A/fr unknown
- 2019-03-07 CR CR20200458A patent/CR20200458A/es unknown
- 2019-03-07 MX MX2023004857A patent/MX2023004857A/es unknown
- 2019-03-07 US US16/976,430 patent/US11466015B2/en active Active
- 2019-03-07 BR BR112020018212-5A patent/BR112020018212A2/pt unknown
- 2019-03-07 MX MX2023004855A patent/MX2023004855A/es unknown
- 2019-03-07 EP EP19712427.4A patent/EP3762389B1/en active Active
- 2019-03-07 MX MX2023004856A patent/MX2023004856A/es unknown
- 2019-03-07 MX MX2020009183A patent/MX2020009183A/es unknown
- 2019-03-07 CA CA3092683A patent/CA3092683A1/en active Pending
- 2019-03-07 CN CN201980017657.XA patent/CN111836812A/zh active Pending
- 2019-03-07 AU AU2019231724A patent/AU2019231724A1/en active Pending
- 2019-03-07 TW TW108107664A patent/TWI823903B/zh active
- 2019-03-07 SG SG11202008641WA patent/SG11202008641WA/en unknown
- 2019-03-07 KR KR1020207028170A patent/KR20200128708A/ko active Search and Examination
-
2020
- 2020-08-20 IL IL276853A patent/IL276853A/en unknown
- 2020-09-03 CL CL2020002284A patent/CL2020002284A1/es unknown
- 2020-09-05 PH PH12020551394A patent/PH12020551394A1/en unknown
- 2020-10-06 CO CONC2020/0012493A patent/CO2020012493A2/es unknown
-
2021
- 2021-02-04 CL CL2021000301A patent/CL2021000301A1/es unknown
- 2021-12-28 CL CL2021003531A patent/CL2021003531A1/es unknown
- 2021-12-28 CL CL2021003536A patent/CL2021003536A1/es unknown
- 2021-12-28 CL CL2021003530A patent/CL2021003530A1/es unknown
-
2022
- 2022-09-28 US US17/954,713 patent/US20230095799A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ744349A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
TN2019000110A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
AR113758A1 (es) | Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
MX2020008237A (es) | Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias. | |
TN2019000107A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
PH12020551394A1 (en) | CRYSTALLINE FORMS OF AN sGC STIMULATOR | |
PH12016502168B1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
JOP20200315A1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
CR20210098A (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
MX2018003186A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[ 4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer. | |
MX337817B (es) | Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas. | |
IL172192A0 (en) | Pyridino [1,2 - a] pyrimidin - 4 - one compounds as anticancer agents | |
MX2017009841A (es) | 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, analogos y sales del mismo y su uso en terapia. | |
WO2007120752A3 (en) | 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders | |
UA99459C2 (en) | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer | |
PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
MXPA04010307A (es) | Derivados 5-oxo y 5-tio de 5h-indeno`1,2-bipiridina con enlace al receptor a2a de la adenosina y actividad inhibidora de la fosfodiesterasa para el tratamiento de trastornos neurodegenerativos y enfermedades relacionadas con la inflamacion. | |
MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
WO2022058745A3 (en) | Imidazo[1,2-a]pyridine compounds and their use in therapy | |
MX2023004924A (es) | Nuevo tratamiento de la atrofia muscular espinal (sma). | |
PH12020551389A1 (en) | Process for preparing soluble guanylate cyclase stimulators | |
MX2021002794A (es) | Metodo mejorado para la fabricacion de 3-[(1s)-1-imidazo[1,2-a]pir idin-6- iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimorficas de la misma. | |
MX2020005847A (es) | Tratamiento del vsr con producto combinado. |